208 related articles for article (PubMed ID: 31094173)
21. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients.
Ma L; Liu J; Wang W; Yang F; Li P; Cai S; Zhou X; Chen X; Zhuang X; Zhang H; Cao G
Future Oncol; 2020 Apr; 16(11):675-686. PubMed ID: 32223423
[No Abstract] [Full Text] [Related]
22. Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response.
Le AK; Zhao C; Hoang JK; Tran SA; Chang CY; Jin M; Nguyen NH; Yasukawa LA; Zhang JQ; Weber SC; Garcia G; Nguyen MH
Aliment Pharmacol Ther; 2017 Sep; 46(6):605-616. PubMed ID: 28766727
[TBL] [Abstract][Full Text] [Related]
23. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
[TBL] [Abstract][Full Text] [Related]
24. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression.
Shen YC; Hsu C; Cheng CC; Hu FC; Cheng AL
Oncology; 2012; 82(5):275-89. PubMed ID: 22555181
[TBL] [Abstract][Full Text] [Related]
25. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract][Full Text] [Related]
26. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
27. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.
Peleg N; Issachar A; Sneh Arbib O; Cohen-Naftaly M; Harif Y; Oxtrud E; Braun M; Leshno M; Barsheshet A; Shlomai A
J Viral Hepat; 2019 Nov; 26(11):1257-1265. PubMed ID: 31243878
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.
Toshikuni N; Arisawa T; Tsutsumi M
World J Gastroenterol; 2014 Mar; 20(11):2876-87. PubMed ID: 24659879
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
El-Serag HB; Kramer J; Duan Z; Kanwal F
J Viral Hepat; 2016 Sep; 23(9):687-96. PubMed ID: 27040447
[TBL] [Abstract][Full Text] [Related]
30. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.
Veldt BJ; Chen W; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; de Knegt RJ; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
Hepatology; 2008 Jun; 47(6):1856-62. PubMed ID: 18506898
[TBL] [Abstract][Full Text] [Related]
31. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
32. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
33. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
34. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
[TBL] [Abstract][Full Text] [Related]
35. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study.
Yen YH; Tsai MC; Wu CK; Chang KC; Hung CH; Chiu KW; Lu SN; Wang JH; Chen CH; Kee KM; Kuo YH; Tseng PL; Lin MT; Huang CM; Lin JT; Hu TH
J Formos Med Assoc; 2018 Sep; 117(9):833-840. PubMed ID: 29089161
[TBL] [Abstract][Full Text] [Related]
36. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
37. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment.
Huang CF; Huang CY; Yeh ML; Wang SC; Chen KY; Ko YM; Lin CC; Tsai YS; Tsai PC; Lin ZY; Chen SC; Dai CY; Huang JF; Chuang WL; Yu ML
EBioMedicine; 2017 Feb; 15():81-89. PubMed ID: 27998720
[TBL] [Abstract][Full Text] [Related]
38. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.
Lee MH; Huang CF; Lai HC; Lin CY; Dai CY; Liu CJ; Wang JH; Huang JF; Su WP; Yang HC; Kee KM; Yeh ML; Chuang PH; Hsu SJ; Huang CI; Kao JT; Chen CC; Chen SH; Jeng WJ; Yang HI; Yuan Y; Lu SN; Sheen IS; Liu CH; Peng CY; Kao JH; Yu ML; Chuang WL; Chen CJ
Sci Rep; 2017 Jun; 7(1):3718. PubMed ID: 28623331
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients.
Aguiar MF; Faria-Janes AL; Garcia-Brandes GI; Takemi-Emori C; Ferraz MLG; Andrade LEC; de Souza AWS
Ann Hepatol; 2019; 18(5):685-692. PubMed ID: 31167733
[TBL] [Abstract][Full Text] [Related]
40. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.
Pereira GH; Peixoto HR; Giusti ML; Souza ML; Victor LB; Fernandes F; Perez RM; Villela-Nogueira CA
Braz J Infect Dis; 2022; 26(5):102697. PubMed ID: 36037847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
